OTCMKTS:IMRSQ

IMRIS Competitors

$0.0070
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range N/A
52-Week Range
$0.00
Now: $0.01
$0.04
VolumeN/A
Average Volume183,218 shs
Market Capitalization$364,210.00
P/E RatioN/A
Dividend YieldN/A
Beta-10.69

Competitors

IMRIS (OTCMKTS:IMRSQ) Vs. NXNN, MAGAA, ARDMQ, ECTE, SCIE, and ULGX

Should you be buying IMRSQ stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to IMRIS, including Nexeon MedSystems (NXNN), Magna-Lab (MAGAA), Aradigm (ARDMQ), Echo Therapeutics (ECTE), SpectraScience (SCIE), and Urologix (ULGX).

Nexeon MedSystems (OTCMKTS:NXNN) and IMRIS (OTCMKTS:IMRSQ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk.

Earnings & Valuation

This table compares Nexeon MedSystems and IMRIS's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nexeon MedSystemsN/AN/AN/AN/AN/A
IMRISN/AN/AN/AN/AN/A

Profitability

This table compares Nexeon MedSystems and IMRIS's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nexeon MedSystemsN/AN/AN/A
IMRISN/AN/AN/A

Risk and Volatility

Nexeon MedSystems has a beta of 12.71, meaning that its share price is 1,171% more volatile than the S&P 500. Comparatively, IMRIS has a beta of -10.69, meaning that its share price is 1,169% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Nexeon MedSystems and IMRIS, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nexeon MedSystems0000N/A
IMRIS0000N/A

Summary

Nexeon MedSystems beats IMRIS on 1 of the 1 factors compared between the two stocks.

IMRIS (OTCMKTS:IMRSQ) and Magna-Lab (OTCMKTS:MAGAA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares IMRIS and Magna-Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMRISN/AN/AN/A
Magna-LabN/A-12.32%42,399.99%

Earnings & Valuation

This table compares IMRIS and Magna-Lab's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMRISN/AN/AN/AN/AN/A
Magna-LabN/AN/A$-130,000.00N/AN/A

Risk & Volatility

IMRIS has a beta of -10.69, meaning that its share price is 1,169% less volatile than the S&P 500. Comparatively, Magna-Lab has a beta of 5.2, meaning that its share price is 420% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for IMRIS and Magna-Lab, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMRIS0000N/A
Magna-Lab0000N/A

Summary

Magna-Lab beats IMRIS on 2 of the 3 factors compared between the two stocks.

Aradigm (OTCMKTS:ARDMQ) and IMRIS (OTCMKTS:IMRSQ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Earnings & Valuation

This table compares Aradigm and IMRIS's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AradigmN/AN/AN/AN/AN/A
IMRISN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Aradigm and IMRIS, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aradigm0000N/A
IMRIS0000N/A

Profitability

This table compares Aradigm and IMRIS's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AradigmN/AN/AN/A
IMRISN/AN/AN/A

Risk & Volatility

Aradigm has a beta of 2.91, suggesting that its stock price is 191% more volatile than the S&P 500. Comparatively, IMRIS has a beta of -10.69, suggesting that its stock price is 1,169% less volatile than the S&P 500.

Summary

Aradigm beats IMRIS on 1 of the 1 factors compared between the two stocks.

IMRIS (OTCMKTS:IMRSQ) and Echo Therapeutics (OTCMKTS:ECTE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for IMRIS and Echo Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMRIS0000N/A
Echo Therapeutics0000N/A

Profitability

This table compares IMRIS and Echo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMRISN/AN/AN/A
Echo TherapeuticsN/AN/AN/A

Volatility and Risk

IMRIS has a beta of -10.69, indicating that its stock price is 1,169% less volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 7.09, indicating that its stock price is 609% more volatile than the S&P 500.

Earnings & Valuation

This table compares IMRIS and Echo Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMRISN/AN/AN/AN/AN/A
Echo TherapeuticsN/AN/AN/AN/AN/A

Summary

Echo Therapeutics beats IMRIS on 1 of the 1 factors compared between the two stocks.

SpectraScience (OTCMKTS:SCIE) and IMRIS (OTCMKTS:IMRSQ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Risk and Volatility

SpectraScience has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, IMRIS has a beta of -10.69, meaning that its share price is 1,169% less volatile than the S&P 500.

Earnings and Valuation

This table compares SpectraScience and IMRIS's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpectraScienceN/AN/AN/AN/AN/A
IMRISN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for SpectraScience and IMRIS, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpectraScience0000N/A
IMRIS0000N/A

Profitability

This table compares SpectraScience and IMRIS's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpectraScienceN/AN/AN/A
IMRISN/AN/AN/A

Summary

SpectraScience beats IMRIS on 1 of the 1 factors compared between the two stocks.

IMRIS (OTCMKTS:IMRSQ) and Urologix (OTCMKTS:ULGX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for IMRIS and Urologix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMRIS0000N/A
Urologix0000N/A

Valuation & Earnings

This table compares IMRIS and Urologix's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMRISN/AN/AN/AN/AN/A
UrologixN/AN/AN/AN/AN/A

Risk & Volatility

IMRIS has a beta of -10.69, indicating that its stock price is 1,169% less volatile than the S&P 500. Comparatively, Urologix has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500.

Profitability

This table compares IMRIS and Urologix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMRISN/AN/AN/A
UrologixN/AN/AN/A

Summary

Urologix beats IMRIS on 1 of the 1 factors compared between the two stocks.


IMRIS Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Nexeon MedSystems logo
NXNN
Nexeon MedSystems
0.7$0.55flat$1.12 millionN/A0.00
MAGAA
Magna-Lab
0.7$0.80flat$943,000.00N/A4.44High Trading Volume
Gap Down
ARDMQ
Aradigm
0.0$0.05flat$764,000.00N/A0.00
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.02flat$234,000.00N/A0.00Gap Up
SCIE
SpectraScience
0.5$0.00flat$177,000.00N/A0.00
ULGX
Urologix
0.6$0.01flat$113,000.00N/A0.00Gap Up
AKSY
Aksys
0.0$0.00flat$0.00N/A0.00
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.40flat$0.00$9.40 million-6.67Increase in Short Interest
News Coverage
Gap Up
HRTT
Heart Tronics
0.0$0.02flat$0.00N/A0.00
IVVI
Ivivi Technologies
0.0$0.00flat$0.00N/A0.00High Trading Volume
NWCI
NewCardio
0.5$0.00flat$0.00N/A0.00
PECN
Photoelectron
0.2$0.03flat$0.00N/A0.00
Trimedyne logo
TMED
Trimedyne
0.4$4.25flat$0.00$5.57 million0.00News Coverage
XCRP
Xcorporeal
0.0$0.00flat$0.00N/A0.00
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.